GlassScriptPhysician profile
Timothy G Abrahamson
NPI 1245239623
$48,883.07
in general payments reported to CMS, 2019-2025
34 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,771 · 2020: $609 · 2021: $721 · 2022: $6,924 · 2023: $16K · 2024: $2,014 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $4,024 · Food and Beverage: $3,510 · Consulting Fee: $1,500 · Education: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,375.00 |
| Travel and Lodging | $4,024.45 |
| Food and Beverage | $3,509.57 |
| Consulting Fee | $1,500.00 |
| Education | $449.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $19,600.39 | 2022-2024 | Opzelura |
| Galderma Laboratories, L.P. | $15,706.67 | 2019-2025 | Nemluvio |
| Abbvie INC. | $4,376.61 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,923.01 | 2019-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,994.81 | 2024-2025 | Spevigo, Cyltezo |
| Ucb, INC. | $560.08 | 2019-2025 | Bimzelx, Cimzia |
| Prugen, INC. Pharmaceuticals | $538.74 | 2019-2020 | |
| Genzyme Corporation | $368.90 | 2022-2025 | |
| Dermavant Sciences, INC. | $333.68 | 2023-2024 | Vtama |
| Lilly USA, LLC | $329.25 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $276.09 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $246.01 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Regeneron Healthcare Solutions, INC. | $238.29 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $229.31 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $177.37 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $174.92 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $107.42 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $97.69 | 2023-2025 | Zoryve |
| Revance Therapeutics, INC. | $90.30 | 2024 | Daxxify |
| Vyne Pharmaceuticals INC. | $78.81 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $74.77 | 2019-2021 | |
| Organogenesis INC. | $59.95 | 2024-2025 | Puraply Wound Matrix |
| Dermira, INC. | $43.02 | 2019-2021 | |
| Celgene Corporation | $34.99 | 2019 | |
| Leo Pharma INC. | $33.56 | 2021-2023 | Adbry |
| Nabriva Therapeutics, Plc | $29.61 | 2022 | |
| Organon LLC | $28.35 | 2025 | Vtama |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Kerecis Limited | $21.20 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Genentech USA, INC. | $20.87 | 2019 | |
| Blueprint Medicines Corporation | $17.60 | 2024 | Ayvakit |
| Fresenius Kabi USA, LLC | $17.20 | 2024 | Idacio |
| Krystal Biotech INC | $15.39 | 2025 | Vyjuvek |
| Mayne Pharma Commercial LLC | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Abrahamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.